CIBC Private Wealth Group
IONS icon

CIBC Private Wealth Group’s Ionis Pharmaceuticals IONS Stock Holding History

CIBC Private Wealth Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$7.83K Buy
99
+88
+800% +$6.63K ﹤0.01% 2497
2025
Q3 		$720 Buy
11
+9
+450% +$439 ﹤0.01% 2857
2025
Q2 		$79 Sell
2
-28
-93% -$916 ﹤0.01% 2983
2025
Q1 		$765 Sell
30
-1,095
-97% -$35.9K ﹤0.01% 2848
2024
Q4 		$38.4K Sell
1,125
-1,300
-54% -$48.6K ﹤0.01% 1784
2024
Q3 		$97.1K Buy
2,425
+300
+14% +$14K ﹤0.01% 1494
2024
Q2 		$100K Sell
2,125
-43
-2% -$1.76K ﹤0.01% 1396
2024
Q1 		$95.3K Buy
+2,168
New +$103K ﹤0.01% 1416
2018
Q4 		– Sell
-10,982
Closed -$567K – 905
2018
Q3 		$567K Sell
10,982
-863
-7% -$40.5K ﹤0.01% 750
2018
Q2 		$493K Sell
11,845
-122
-1% -$5.41K ﹤0.01% 781
2018
Q1 		$527K Buy
11,967
+566
+5% +$28.8K ﹤0.01% 776
2017
Q4 		$574K Buy
+11,401
New +$625K ﹤0.01% 751

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

CIBC Private Wealth Group's IONS Position: Q4 2025 in Review

CIBC Private Wealth Group increased its Ionis Pharmaceuticals (IONS) stake by 800% in Q4 2025, buying an estimated $6.63K and bringing the position to 99 shares worth $7.83K. The position accounts for ﹤0.01% of the portfolio, ranked #2497.

CIBC Private Wealth Group first reported a position in IONS in Q4 2017 and has held it in 12 quarters since. The position peaked at $574K in Q4 2017. 491 funds tracked by Wall St. Rank hold IONS as of Q4 2025.

  • CIBC Private Wealth Group held 99 shares of Ionis Pharmaceuticals worth $7.83K as of Q4 2025.
  • CIBC Private Wealth Group bought 88 Ionis Pharmaceuticals shares in Q4 2025, an estimated $6.63K.
  • Ionis Pharmaceuticals made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #2497 holding.
  • CIBC Private Wealth Group first reported a position in Ionis Pharmaceuticals in Q4 2017 and has held it in 12 quarters since.
  • CIBC Private Wealth Group's Ionis Pharmaceuticals position peaked at $574K in Q4 2017.
  • 491 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.